The ASX 200 Health Equity Index (XHJ) is down 2.40% at the time of writing, compared to the broader ASX 200 index which has fallen 0.60%.

Imaging Technology Company, Mach7 technology (ASX: M7T), jumped 6.5% this morning after receiving a buy order for its medical imaging platforms.

The order was for the full suite of its products: the Mach7 Enterprise Imaging Platform, eUnity Diagnostic Viewer, eUnity Enterprise Viewer, and the Mach7 Universal Worklist.

The $ 3.6 million order was received from US-based Trinity Health and is in addition to the 7-year agreement Trinity already signed in November to purchase eUnity Enterprise Viewer.

Today’s deal also means that Mach7 will provide Trinity with a complete Imaging, Archiving and Communications System (PACS) diagnostic solution, for a maximum potential contract value of $ 15.6 million on seven years.

Mach7’s imaging platform creates a complete view of the patient to perform diagnosis and reduce the time and cost of providing care.

The company has licensed the platform to other customers such as St Luke’s Boise Medical Center.

Mach7 also just completed a strong FY21, reporting a 95% increase in sales to $ 25.6 million.

M7TShare price today:

Elsewhere in health, there were notable declines across the big end of town, led by radiology group Pro Medicus (ASX: PME) which fell more than 5% on no news.

Although still showing strong growth over the year, shares of SMEs fell by around 17% in the past month.

There were also big drops for CSL (ASX: CSL) and Sonic Healthcare (ASX: SHL), both down 3% with no news.

Other small caps in ASX healthcare with notable announcements

Australian Clinical Laboratories (ASX: ACL) + 3.5%

The pathology service provider improved its earnings forecast compared to the IPO prospectus.

The company said total first-half revenue will now range between $ 398.1 million and $ 414.0 million, compared to $ 307.4 million forecast in the prospectus.

Australian Clinical Labs, which was enrolled in May, is the third largest pathology network in Australia. Pathology is a branch of medicine that tests for diseases, including (but not limited to) COVID-19.

Imricor Medical Systems (ASX: IMR) unchanged

Another medical device company, Imricor, also announced a sales agreement with US company MiRTLE Medical.

Under the terms, Imricor will be a non-exclusive distributor of MiRTLE’s 12-lead ECG (electrocardiography) system.

MiRTLE’s 12-lead ECG monitor presents interference-free ECG signals to a cardiologist and triggers MRI during a heartbeat, allowing MRI to produce sharp images of the heart.

Telix Pharma (ASX: TLX) -1%

The company received a $ 12.1 million research and development (R&D) tax refund from the ATO for its operations during the fiscal year ended December 31, 2020.

Telix also said its request to expand overseas findings to allow partial recovery of essential overseas R&D spending has been accepted by the Ministry of Industry, Science, Energy and Technology. Resources.

Stock prices today:


You might be interested in